Table 1

Cases with Alterations of Clinical Significance Identified by BAC and Oligo aCGH.

Pt. #

Chr

Band

Start pos.

End pos.

Gain/Loss

Size

# of BACs

# of Oligos


21637

chr16

p11.2

29,563,985

30,066,187

Loss

502,202

5

46


21992

chr16

p11.2

29,563,985

30,066,187

Loss

502,202

5

46


22013

chr16

p11.2

29,563,985

30,066,187

Loss

502,202

5

46


21993

chr10

q25.2q25.3

114,306,207

114,925,368

Loss

619,161

3

36


21756

chr2

q35

219,418,281

220,060,969

Loss

642,688

2

43


22002

chr2

q37.3

239,664,393

240,400,008

Loss

735,615

3

82


22334

chr10

q25.2q25.3

114,024,053

115,677,301

Gain

1,653,248

3

53


21688

chr16

p13.11p12.3

15,056,257

16,742,812

Gain

1,686,555

3

61


21667

chr17

p12

14,052,297

15,742,271

Gain

1,689,974

3

67

21896

chr4

q35.2

189,407,487

191,133,809

Loss

1,726,322

8

147


22269

chr2

q12.3q13

107,945,041

109,784,684

Loss

1,839,643

6

102


21640

chr19

q13.42

59,272,450

61,239,237

Gain

1,966,787

8

135


22117

chr9

q33.1

118,991,777

121,063,590

Gain

2,071,813

3

67


22066

chr8

p12p11.21

38,303,146

40,515,492

Gain

2,212,346

6

104


21786

chr1

q21.1

144,973,942

147,421,814

Gain

2,447,872

5

63


22237

chr1

q21.1

144,973,942

147,421,814

Gain

2,447,872

5

63


22310

chr22

q11.21

17,299,742

19,770,655

Loss

2,470,913

13

205


22050

chr22

q11.21

17,007,819

19,770,655

Loss

2,762,836

13

208


21936

chr1

q21.1

144,973,942

147,966,185

Gain

2,992,243

5

65


21719

chr2

q31.1

169,823,689

172,870,083

Loss

3,046,394

8

119


22128

chr4

q34.3

179,065,989

182,435,119

Loss

3,369,130

3

91


22006

chr17

p11.2

16,723,071

20,145,604

Loss

3,422,533

18

311


22174

chr1

q41q42.12

221,260,860

224,709,317

Loss

3,448,457

9

178


21971

chr22

q11.23q12.2

24,025,269

28,008,109

Loss

3,982,840

3

111


22073

chr15

q11.2q13.1

21,208,177

26,194,049

Loss

4,985,872

11

281


21687

chr16

q12.2q21

51,912,655

57,173,018

Loss

5,260,363

15

261


21975

chr5

p15.2p14.3

13,514,464

18,988,928

Loss

5,474,464

3

122


21555

chr7

p22.3p22.1

153,644

6,230,285

Gain

6,076,641

32

434


21547

chr2

q24.3q31.1

168,702,606

174,842,496

Loss

6,139,890

11

226


21755

chr11

p12p11.2

37,540,680

43,940,573

Loss

6,399,893

14

298


21761

chr3

p14.1p12.3

70,738,914

77,275,908

Loss

6,536,994

6

151


22151

chr15

q11.2q13.1

18,809,804

26,194,049

Gain

7,384,245

14

331


22322

chr8

p21.3p12

22,954,212

30,630,828

Loss

7,676,616

9

224


21889

chr2

q33.1q34

202,901,021

211,366,732

Gain

8,465,711

13

281


21723

chr5

q23.1q23.3

121,487,477

130,306,377

Loss

8,818,900

4

204


22337

chr1

p36.22p36.13

9,476,880

19,436,653

Loss

9,959,773

21

436


21795

chr1

p34.2p32.3

41,201,837

55,191,500

Gain

13,989,663

17

440


20986

chr12

p13.33p12.3

84,918

17,505,135

Gain

17,420,217

46

800


21957

chr11

q23.3q25

116,478,434

134,419,382

Gain

17,940,948

40

784


21596

chr1

q25.1q32.1

173,519,967

203,663,817

Gain

30,143,850

25

814


22055

chr3

p14.1p13

71,164,161

71,958,845

Loss

794,684

3

46


21566*

chr17

p13.2p13.1

6,081,457

6,904,679

Loss

823,222

3

14


21558

chr22

q13.33

48,567,185

49,517,230

Loss

950,045

6

54


21770

chr8

p23.3

202,505

1,411,517

Loss

1,209,012

5

96


22254

chr8

p23.2

2,604,280

3,966,809

Loss

1,362,529

9

140


21937

chr7

q11.23

72,404,049

73,771,409

Loss

1,367,360

10

158


21710

chr15

q13.2q13.3

28,741,818

30,186,356

Loss

1,444,538

3

64


21722

chr15

q13.2q13.3

28,741,818

30,226,376

Loss

1,484,558

3

65


21739

chr15

q13.2q13.3

28,741,818

30,226,376

Loss

1,484,558

3

65


21787

chr15

q13.2q13.3

28,741,818

30,226,376

Loss

1,484,558

3

65


21897*

chr5

p15.2

8,511,592

9,888,817

Gain

1,377,225

34

29


21884

chrX

q28

152,676,750

153,059,428

Gain

382,678

3

44


21592

chrX

p22.33q28

701

154,888,083

Gain

154,887,382

325

6888


22087

chrY

p11.32

262,578

57,715,879

Gain

57,453,301

49

49


22285

chrX

p21.1

31,759,551

31,830,811

Loss

71,260

2

11


22244

chr22

q13.33

49,342,961

49,514,486

Loss

171,525

2

56


*additional alterations identified by oligonucleotide aCGH.


Neill et al. Molecular Cytogenetics 2010 3:11   doi:10.1186/1755-8166-3-11

Open Data